SCHEMBL2964026

SCHEMBL2964026

Cc1ccc(Sc2cccc(C(N)=O)c2)c(Nc2ccnc3nc(C)ccc23)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.36
MAP2K4 P45985 1/20 0.35
PIM1 P11309 1/20 0.35
AKT2 P31751 1/20 0.35
ICAM1 P05362 2/20 0.35
SELE P16581 2/20 0.35
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35
ROCK1 Q13464 1/20 0.34
VCAM1 P19320 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
YES1 P07947 1/20 0.34
LYN P07948 1/20 0.34
FGR P09769 1/20 0.34
EPHA1 P21709 1/20 0.34
EPHA2 P29317 1/20 0.34
EPHA3 P29320 1/20 0.34
EPHB2 P29323 1/20 0.34
CSK P41240 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961459 0.90 POLB (0.38) PIM1AKT2
SCHEMBL2019054 0.90 ICAM1 (0.40) MAP2K4PIM1AKT2ICAM1SELE
SCHEMBL2956184 0.89 EPHB4 (0.36) PIM1AKT2FYN
SCHEMBL2960103 0.89 KDM4E (0.33) PARP1MAP2K4ICAM1SELERAF1
SCHEMBL2970305 0.87 PIM1 (0.38) PIM1AKT2ICAM1SELE
SCHEMBL2021057 0.85 PIM1 (0.41) PIM1AKT2LCK
SCHEMBL2968577 0.84 KDR (0.41) PIM1AKT2SYKSIRT2
SCHEMBL2018796 0.84 PIM1 (0.42) PIM1AKT2
SCHEMBL2968986 0.82 PIM1 (0.41) PIM1AKT2ICAM1SELEVCAM1
SCHEMBL2959916 0.81 PIM1 (0.38) PIM1AKT2ICAM1SELEVCAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PARP1 1805/4885MAP2K4 3698/4885PIM1 2963/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 PARP1 1805/4885MAP2K4 3698/4885PIM1 2963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.